EUVIMEDEUVIMED entdecken
Open Access

Value of increased soluble suppressor tumorigenicity biomarker 2 (sST2) on admission as an indicator of severity in patients with COVID-19

María Arnaldos-Carrillo, José Antonio Noguera-Velasco, Isabel M Martínez-Ardil, Alejandro Riquelme-Pérez, Iria Cebreiros-López, Álvaro Hernández-Vicente, José Antonio Ros-Lucas, Amjad Khan, Antoni Bayes-Genís, Domingo Pascual-Figal

Medicina Clínica · 2023

DOI: 10.1016/j.medcli.2023.04.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicina Clínica, 2023. Verfasst von María Arnaldos-Carrillo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Laboratory Service, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain; Universidad de Murcia, Murcia, Spain. Hauptthemen laut MEDLINE: Interleukin-1 Receptor-Like 1 Protein, COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Soluble suppressor of tumorigenicity-2 (sST2) is a biomarker for heart failure and pulmonary injury. We hypothesize that sST2 could help predict severity of SARS-CoV-2 infections. METHODS: sST2 was analyzed in patients consecutively admitted for SARS-CoV-2 pneumonia. Other prognostic markers were also measured. In-hospital complications were registered, including death, ICU admission, and respiratory support requirements. RESULTS: 495 patients were studied (53% male, age: 57.6±17.6). At admission, median sST2 concentrations was 48.5ng/mL [IQR, 30.6-83.1ng/mL] and correlated with male gender, older age, comorbidities, other severity biomarkers, and respiratory support requirements. sST2 levels were higher in patients who died (n=45, 9.1%) (45.6 [28.0, 75.9]ng/mL vs. 144 [82.6, 319] ng/mL, p 210ng/mL were a strong predictor of complicated in-hospital courses, with higher risk of death (OR, 39.3, CI95% 15.9, 103) and death/ICU (OR 38.3, CI95% 16.3-97.5) after adjusting for all other risk factors. The addition of sST2 enhanced the predictive capacity of mortality risk models. CONCLUSIONS: sST2 represents a robust severity predictor in COVID-19 and could be an important tool for identifying at-risk patients who may benefit from closer follow-up and specific therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-1 Receptor-Like 1 ProteinCOVID-19HumansMaleAdultMiddle AgedAgedFemalePrognosisSARS-CoV-2Biomarkers

Stichwörter der Autor:innen

COVID-19 pneumoniaEstratificación de riesgoNeumonía por COVID-19Risk stratificationsST2

Substanzen

Interleukin-1 Receptor-Like 1 ProteinBiomarkers

Autor:innen und Institutionen

  • Clinical Laboratory Service, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain; Universidad de Murcia, Murcia, Spain.
  • Clinical Laboratory Service, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain; Universidad de Murcia, Murcia, Spain; IMIB Pascual Parrilla, Murcia, Spain.
  • Family and Community Medicine, Servicio Murciano de Salud, Murcia, Spain.
  • Universidad de Murcia, Murcia, Spain; CIBER Cardiovascular, Madrid, Spain.
  • Universidad de Murcia, Murcia, Spain.
  • Pneumology Service, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain; Universidad Católica de Murcia (UCAM), Murcia, Spain.

Zitieren

APA

Arnaldos-Carrillo, M., Noguera-Velasco, J. A., Martínez-Ardil, I. M., Riquelme-Pérez, A., Cebreiros-López, I., Hernández-Vicente, Á., Ros-Lucas, J. A., Khan, A., Bayes-Genís, A., & Pascual-Figal, D. (2023). Value of increased soluble suppressor tumorigenicity biomarker 2 (sST2) on admission as an indicator of severity in patients with COVID-19. Medicina Clínica. https://doi.org/10.1016/j.medcli.2023.04.005

Vancouver

Arnaldos-Carrillo M, Noguera-Velasco JA, Martínez-Ardil IM, Riquelme-Pérez A, Cebreiros-López I, Hernández-Vicente Á, et al. Value of increased soluble suppressor tumorigenicity biomarker 2 (sST2) on admission as an indicator of severity in patients with COVID-19. Medicina Clínica. 2023. doi:10.1016/j.medcli.2023.04.005

BibTeX
@article{ArnaldosCarrillo2023,
  author = {Arnaldos-Carrillo, María and Noguera-Velasco, José Antonio and Martínez-Ardil, Isabel M and Riquelme-Pérez, Alejandro and Cebreiros-López, Iria and Hernández-Vicente, Álvaro and Ros-Lucas, José Antonio and Khan, Amjad and Bayes-Genís, Antoni and Pascual-Figal, Domingo},
  title = {Value of increased soluble suppressor tumorigenicity biomarker 2 (sST2) on admission as an indicator of severity in patients with COVID-19},
  journal = {Medicina Clínica},
  year = {2023},
  doi = {10.1016/j.medcli.2023.04.005}
}
Kostenlos starten →